S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:RDHL

RedHill Biopharma (RDHL) Stock Price, News & Analysis

$0.53
+0.01 (+1.94%)
(As of 03/28/2024 ET)
Today's Range
$0.50
$0.55
50-Day Range
$0.46
$1.08
52-Week Range
$0.26
$4.92
Volume
500,785 shs
Average Volume
1.32 million shs
Market Capitalization
$15.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RDHL stock logo

About RedHill Biopharma Stock (NASDAQ:RDHL)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

RDHL Stock Price History

RDHL Stock News Headlines

RedHill Biopharma Receives New Patent For H. Pylori Treatment Talicia
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
RedHill Biopharma Ltd. ADR
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Why Redhill Biopharma Stock Is Moving Higher
5 Investors Betting Big on RedHill Biopharma (RDHL) Stock
RedHill's Talicia Granted 5-year Market Exclusivity By FDA
See More Headlines
Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/30/2021
Today
3/28/2024
Next Earnings (Estimated)
4/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RDHL
Employees
113
Year Founded
N/A

Profitability

Net Income
$-71,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$61.80 million
Book Value
($16.41) per share

Miscellaneous

Free Float
27,680,000
Market Cap
$15.62 million
Optionable
No Data
Beta
3.48
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Dror Ben-Asher (Age 58)
    Co-Founder, Chairman & CEO
    Comp: $594.61k
  • Mr. Razi Ingber (Age 40)
    Chief Financial Officer
    Comp: $339.82k
  • Mr. Gilead Raday MPhil (Age 49)
    MSc, Chief Operating Officer
    Comp: $365.56k
  • Mr. Adi Frish (Age 54)
    Chief Corporate & Business Development Officer
    Comp: $339.3k
  • Mr. Rick D. Scruggs (Age 64)
    Chief Commercial Officer, President of RedHill Biopharma Inc. & Director
    Comp: $469.8k
  • Ms. Alexandra Okmian
    Senior Business Development & Investor Relations Manager
  • Dr. Reza Fathi Ph.D. (Age 69)
    Senior Vice President of Research & Development
    Comp: $299.29k
  • Mr. Guy Goldberg J.D. (Age 48)
    Chief Business Officer
    Comp: $338.13k
  • Dr. June S. Almenoff FACP (Age 67)
    M.D., Ph.D., Chief Medical Officer
  • Ms. Patricia Anderson B.Sc. RAC
    Senior Vice President of Regulatory Affairs

RDHL Stock Analysis - Frequently Asked Questions

How have RDHL shares performed in 2024?

RedHill Biopharma's stock was trading at $1.46 at the start of the year. Since then, RDHL stock has decreased by 64.0% and is now trading at $0.5260.
View the best growth stocks for 2024 here
.

Are investors shorting RedHill Biopharma?

RedHill Biopharma saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,060,000 shares, an increase of 181.8% from the February 29th total of 376,200 shares. Based on an average daily trading volume, of 1,370,000 shares, the short-interest ratio is currently 0.8 days. Approximately 3.6% of the company's stock are sold short.
View RedHill Biopharma's Short Interest
.

When is RedHill Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our RDHL earnings forecast
.

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) posted its quarterly earnings results on Tuesday, November, 30th. The biotechnology company reported ($20.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($19.20) by $0.80. The biotechnology company earned $21.61 million during the quarter, compared to analysts' expectations of $23.41 million. RedHill Biopharma had a negative trailing twelve-month return on equity of 328.99% and a net margin of 354.95%. During the same quarter last year, the business posted ($20.00) earnings per share.

When did RedHill Biopharma's stock split?

RedHill Biopharma's stock reverse split before market open on Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).

Who are RedHill Biopharma's major shareholders?

RedHill Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of RedHill Biopharma?

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RDHL) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners